Guardant Health

Guardant Health is a precision oncology company founded in 2012 that develops liquid biopsy technologies for cancer detection and management. Its work spans genomic profiling, real-world evidence generation, and diagnostics, serving oncologists and biopharma partners across the Americas, Europe, Asia, the Middle East, and Africa. The company operates CLIA-certified, CAP-accredited laboratories and has performed over 500,000 blood tests to date.

Several of Guardant Health's products hold significant regulatory milestones. Shield is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older. Guardant360 CDx was the first FDA-approved blood test for comprehensive genomic profiling in advanced cancer management. Guardant Reveal focuses on early-stage cancer detection. Collectively, approximately 12,000 physicians use the company's testing portfolio.

The company's technical domains include liquid biopsy, precision oncology, genomic profiling, and real-world evidence. Guardant Health states its mission as conquering cancer with data.